Zymeworks (NASDAQ:ZYME) Raised to “Hold” at Wells Fargo & Company

Zymeworks (NASDAQ:ZYME) was upgraded by Wells Fargo & Company to a “hold” rating in a research report issued on Friday,Zacks.com reports.

A number of other equities research analysts also recently commented on ZYME. Wall Street Zen downgraded Zymeworks from a “strong-buy” rating to a “buy” rating in a research report on Sunday, October 19th. B. Riley upgraded Zymeworks to a “strong-buy” rating in a research report on Thursday, October 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zymeworks in a research report on Friday. Finally, HC Wainwright upgraded Zymeworks from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 14th. Two investment analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy”.

Zymeworks Price Performance

Shares of ZYME stock opened at $17.74 on Friday. Zymeworks has a 12-month low of $9.03 and a 12-month high of $19.50. The company has a market cap of $1.33 billion, a price-to-earnings ratio of -18.29 and a beta of 1.51. The business has a 50 day simple moving average of $16.18.

Zymeworks (NASDAQ:ZYME) last released its earnings results on Tuesday, November 8th. The company reported ($1.14) earnings per share for the quarter. The firm had revenue of $4.40 million during the quarter. Zymeworks had a negative return on equity of 21.59% and a negative net margin of 59.96%.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.